Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma

Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma

Abstract. Background:. Circulating tumor DNA (ctDNA) is a promising biomarker for non-invasive epidermal growth factor receptor mutations (EGFRm) detection in lung cancer patients, but existing methods have limitations in sensitivity and availability. In this study, we used the ΔCt value (mutant cyc...

Full description

Bibliographic Details
Main Authors:	Xiang-Liang Liu, Ri-Lan Bai, Xiao Chen, Yu-Guang Zhao, Xu Wang, Ke-Wei Ma, Hui-Min Tian, Fu-Jun Han, Zi-Ling Liu, Lei Yang, Wei Li, Fei Gai, Jiu-Wei Cui, Pei-Fang Wei
Format:	Article
Language:	English
Published:	Wolters Kluwer 2021-10-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000001760

Similar Items

Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis
by: Fei SU, et al.
Published: (2018-05-01)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
by: Yu Wang, et al.
Published: (2021-10-01)

Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients
by: Anna Buder, et al.
Published: (2021-04-01)

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma
by: Zhanyu Xu, et al.
Published: (2021-08-01)

Comparative Analysis of Two Methods for the Detection of <i>EGFR</i> Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
by: Ming-Szu Hung, et al.
Published: (2019-06-01)

Relationship between EGFR, ALK Gene Mutation and Imaging  and Pathological Features in Invasive Lung Adenocarcinoma
by: He YANG, et al.
Published: (2022-03-01)

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
by: Chul Kim, et al.
Published: (2021-07-01)

Dual-energy CT-based radiomics in predicting EGFR mutation status non-invasively in lung adenocarcinoma
by: Jing-Wen Ma, et al.
Published: (2024-01-01)

Relationship between EGFR Mutations and Pathological Classification and  Specimen of Lung Adenocarcinoma
by: Lifei KANG, et al.
Published: (2017-06-01)

Circulating <i>EGFR</i> Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study
by: Shih-Hong Li, et al.
Published: (2022-09-01)

Role of the Expression Level of Nrf2 in Predicting Response of EGFR-TKIs  in Lung Adenocarcinoma Patients with EGFR Gene Mutations
by: Xiang ZHU, et al.
Published: (2014-02-01)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas.
by: Jaeyoung Cho, et al.
Published: (2016-01-01)

Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma
by: Hui ZHANG, et al.
Published: (2015-11-01)

DOK2 inhibits EGFR-mutated lung adenocarcinoma.
by: Alice H Berger, et al.
Published: (2013-01-01)

EGFR Mutation Status in Uighur Lung Adenocarcinoma Patients
by: Li SHAN, et al.
Published: (2013-02-01)

Outcomes of salvage lung resections in advanced EGFR‐mutant lung adenocarcinomas under EGFR TKIs
by: Ying‐Yuan Chen, et al.
Published: (2021-10-01)

Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas
by: Wu Shafei, et al.
Published: (2010-07-01)

Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study
by: Helen Brooks, et al.
Published: (2023-07-01)

Observation on the clinical efficacy and side effects of EGFR-TKI ± chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma
by: Jianping Zheng, et al.
Published: (2022-12-01)

The relationship between EGFR mutation and metastasis pattern in lung adenocarcinoma
by: Ismail Beypinar, et al.
Published: (2019-08-01)

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
by: Toshihide Nishimura, et al.
Published: (2020-08-01)

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
by: Ruofei Yu, et al.
Published: (2021-09-01)

Conventional transbronchial needle aspiration is promising for identifying EGFR mutations in lung adenocarcinoma
by: Li‐Han Hsu, et al.
Published: (2019-04-01)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
by: Jiang-Yong Yu, et al.
Published: (2016-03-01)

Double-Stranded DNA in Exosomes of Malignant Pleural Effusions as a Novel DNA Source for EGFR Mutation Detection in Lung Adenocarcinoma
by: Xueling Qu, et al.
Published: (2019-09-01)

Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations
by: Guowei ZHANG, et al.
Published: (2022-09-01)

Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations
by: Hongyue Qin, et al.
Published: (2022-09-01)

Predictive Role of EGFR Mutation Status on Postoperative Prognosis in Patients  with Resected Lung Adenocarcinomas
by: Hao BAI, et al.
Published: (2013-04-01)

Correlation between Immune Microenvironment Features and EGFR Mutation Status  in Lung Adenocarcinoma
by: Hongyu ZHU, et al.
Published: (2023-03-01)

Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma.
by: Chun-Yu Lin, et al.
Published: (2017-01-01)

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report
by: Eric Dansin, et al.
Published: (2015-03-01)

The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas.
by: Wan Shanzhi, et al.
Published: (2014-01-01)

Correlation between EGFR mutation status and F18‐fluorodeoxyglucose positron emission tomography‐computed tomography image features in lung adenocarcinoma
by: Lei Zhu, et al.
Published: (2019-04-01)

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
by: Yuan Gao, et al.
Published: (2017-07-01)

Relationship between the image characteristics of artificial intelligence and EGFR gene mutation in lung adenocarcinoma
by: Guoping Zhou, et al.
Published: (2023-01-01)

The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs
by: Weiguo Gu, et al.
Published: (2024-02-01)

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
by: Shouzheng Wang, et al.
Published: (2019-06-01)

Efficacy of Gefitinib for Young Patients with Unknown EGFR Gene Mutation  in Advanced Lung Adenocarcinoma
by: Yutao LIU, et al.
Published: (2014-05-01)

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of <i>EGFR</i>-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable <i>EGFR</i> Mutations in Cerebrospinal Fluid
by: Pei-Ya Liao, et al.
Published: (2022-06-01)

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
by: Yanxin Chen, et al.
Published: (2019-08-01)